Jul. 17 at 1:09 AM
The
$XBI surged 27% between 6/10/26 (the last time the XBI closed under
$130) & last Thursday7/9/26, but has since fallen 7.5% over the last 5 trading days.
Attached are changes in share price for all commercial-stage oncology focused bios (MC's over
$450MM) over the subject period.
$VSTM &
$URGN are the biggest gainers over the last 5 weeks. VSTM still appears quite cheap if analyst estimates around its combo therapy are credible & if the combo's value proposition is consistent with CTIC's Vonjo acquired for
$1.7B. VSTM 7375 compound is also interesting.
The evidence suggests an URGN M&A exit could be imminent. More to come on URGN shortly.
$LEGN 's partner reported Q226 Carvykti sales yesterday after the close. As near as we can tell, sales missed Q226 consensus per Seeking Alpha by ~10%.
$NVCR is the only bio in this peer group down the last 5 weeks, we suspect due to their TTF Phase 3 trial in brain cancer did not meet its endpoint.
As always, this is not investment advice.
